Endnotes: (1) SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not have ...
Novel triple-drug HCV combo achieves high SVR Direct-acting investigational "three-D" combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.
NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with ...
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection ...
Healthcare worker HIV PEP guidelines updated Rates of sustained virologic response ranged from 70% to 90% among patients with HCV and HIV coinfection in the PHOTON-1 study. The first interferon-free ...
In more than 700 chronic HCV patients without cirrhosis who were infected with one of genotypes 1-6 (GT1-6) and were new to treatment, 97.5 percent (n=693/711) achieved sustained virologic response at ...
AMSTERDAM, April 20, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected patients with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Of those who completed treatment, 92% had undetectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results